Takeda Pharmaceutical Company Limited (TAK)

Revenue Breakdown 2

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016	Mar 31, 2015	Mar 31, 2014	Mar 31, 2013
GI Revenue	1.49T	1.41T	1.36T
Rare Diseases Revenue	777.90B	762.70B	752.82B
PDT Revenue	1.10T	1.06T	1.03T
Oncology Revenue	609.20B	580.13B	560.43B
Vaccines Revenue	64.60B	59.61B	55.41B
Neuroscience Revenue	429.10B	414.34B	565.82B
Other Product Revenue	219.70B	223.96B	257.39B
Revenue (Total)	4.69T	4.51T	4.58T

Revenue by Geography

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016	Mar 31, 2015	Mar 31, 2014	Mar 31, 2013
Japan Revenue	427.90B	433.11B	418.46B
United States Revenue	2.20T	2.16T	2.38T
Latin America Revenue	280.10B	254.13B	235.85B
China Revenue	208.70B	195.14B	191.74B
Asia (ex-Japan & China) Revenue	105.50B	98.67B	99.39B
Asia (ex-Japan) Revenue	314.20B	293.81B	291.13B
Russia / CIS Revenue	89.30B	79.72B	72.36B
Europe and Canada Revenue	-	1.15T	1.06T
Other Geographic Revenue (Pre-FY2027 Reporting)	-	133.89B	128.85B
Revenue (Other)	-100.00M	-	1.00M
Revenue (Total)	4.69T	4.51T	4.58T

Data Source: Fiscal.ai Last updated: Oct 30, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 4, 2026

Data Sources Report a data error